Free Newsletter
Embryo engineering breakthrough triggers criticism
Stem cell researchers at Cornell have genetically engineered a human embryo, a pioneering development that was immediately condemned as a big step toward designing babies. The work itself was very simple: After putting a fluorescent protein gene into an embryo all the cells in the embryo glowed after it divided, giving researchers a chance to track the changes that had been engineered. The scientists emphasized that their work was done on a nonviable embryo that could never have grown into a baby.
The work, first covered by The Sunday Times, was criticized by the Center for Genetics and Society for crossing a boundary that had never been breached. Their concern is that once researchers understand how to engineer an embryo, people can design their babies with particular attributes for appearance, intelligence or athletic ability. But the scientists say the work shouldn't be misinterpreted.
"None of us wants to make designer babies," said Dr. Zev Rosenwaks, director of the Center for Reproductive Medicine and Infertility at New York-Presbyterian/Weill Cornell Medical Center.
- read the article in the New York Times
Related Articles:
Cloning advance could lead to designer babies
Human embryo clones unveiled by CA scientists
Cloning project makes a major breakthrough
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: